Skip to main content
Premium Trial:

Request an Annual Quote

Goldman Sachs Reinstates Neutral Rating for Agilent

NEW YORK (GenomeWeb) – Goldman Sachs today reinstated a Neutral rating for Agilent Technologies with a 12-month price target on the company's shares of $58.

As Agilent proceeds on the separation of its electronic measurement business into a separate publicly traded firm called Keysight Technologies, analyst Isaac Ro said in a research note that the global funding environment and emerging markets remain stable and the company's investments into its mass spectrometry and diagnostics businesses will help it gain incremental market share.

He added, though, that Agilent's recent earnings results have been "inconsistent relative to consensus expectations," and that while there is potential for M&A following the split, "we believe current valuations already appropriately capture this potential. Meanwhile, we believe fundamentals in the EMG business remain modestly challenged given secular pressures (price competition, shift to software-based platforms) in core end markets."

Goldman Sachs moved Agilent to a Not Rated status in September following the announcement of the firm's planned separation into two separate entities. At the time, the investment bank said that it changed Agilent's rating status due to the fact that it "is acting as a financial advisor in connection with a matter that is fundamental to the reasonable analysis of the rating and price target for this stock."

In afternoon trading on the New York Stock Exchanges, shares of Agilent were down a fraction of 1 percent to $58.22

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.